Mortality in cancer patients with SARS-CoV-2 or seasonal influenza: an observational cohort study from a German-wide hospital network.


Journal

Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307

Informations de publication

Date de publication:
Feb 2023
Historique:
received: 20 02 2022
accepted: 07 05 2022
pubmed: 4 6 2022
medline: 31 1 2023
entrez: 3 6 2022
Statut: ppublish

Résumé

At the beginning of the COVID-19 pandemic, SARS-CoV-2 was often compared to seasonal influenza. We aimed to compare the outcome of hospitalized patients with cancer infected by SARS-CoV-2 or seasonal influenza including intensive care unit admission, mechanical ventilation and in-hospital mortality. We analyzed claims data of patients with a lab-confirmed SARS-CoV-2 or seasonal influenza infection admitted to one of 85 hospitals of a German-wide hospital network between January 2016 and August 2021. 29,284 patients with COVID-19 and 7442 patients with seasonal influenza were included. Of these, 360 patients with seasonal influenza and 1625 patients with COVID-19 had any kind of cancer. Cancer patients with COVID-19 were more likely to be admitted to the intensive care unit than cancer patients with seasonal influenza (29.4% vs 24.7%; OR 1.31, 95% CI 1.00-1.73 p < .05). No statistical significance was observed in the mechanical ventilation rate for cancer patients with COVID-19 compared to those with seasonal influenza (17.2% vs 13.6% OR 1.34, 95% CI 0.96-1.86 p = .09). 34.9% of cancer patients with COVID-19 and 17.9% with seasonal influenza died (OR 2.45, 95% CI 1.81-3.32 p < .01). Risk factors among cancer patients with COVID-19 or seasonal influenza for in-hospital mortality included the male gender, age, a higher Elixhauser comorbidity index and metastatic cancer. Among cancer patients, SARS-CoV-2 was associated with a higher risk for in-hospital mortality than seasonal influenza. These findings underline the need of protective measurements to prevent an infection with either COVID-19 or seasonal influenza, especially in this high-risk population.

Identifiants

pubmed: 35657531
doi: 10.1007/s15010-022-01852-5
pii: 10.1007/s15010-022-01852-5
pmc: PMC9163872
doi:

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

119-127

Informations de copyright

© 2022. The Author(s).

Références

Piroth L, et al. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2021;9:251–9.
doi: 10.1016/S2213-2600(20)30527-0
ElGohary GM et al. The risk and prognosis of COVID-19 infection in cancer patients: a systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2020. https://doi.org/10.1016/j.hemonc.2020.07.005
doi: 10.1016/j.hemonc.2020.07.005
Auvinen R, et al. Comparison of the clinical characteristics and outcomes of hospitalized adult COVID-19 and influenza patients—a prospective observational study. Infect Dis. 2021;53:111–21.
doi: 10.1080/23744235.2020.1840623
Rüthrich MM, et al. COVID-19 in cancer patients: clinical characteristics and outcome—an analysis of the LEOSS registry. Ann Hematol. 2021;100:383–93.
doi: 10.1007/s00277-020-04328-4
Collins JP, et al. Outcomes of immunocompromised adults hospitalized with laboratory-confirmed influenza in the United States, 2011–2015. Clin Infect Dis. 2020;70:2121–30.
doi: 10.1093/cid/ciz638
Memoli MJ, et al. The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. Clin Infect Dis. 2014;58:214–24.
doi: 10.1093/cid/cit725
Rieck T, et al. Impfquoten bei Erwachsenen in Deutschland—Aktuelles aus der KV-Impfsurveillance und der Onlinebefragung von Krankenhauspersonal. OKaPII. 2020;47:3–26.
Brehm TT, et al. Comparison of clinical characteristics and disease outcome of COVID-19 and seasonal influenza. Sci Rep. 2021;11:1–10.
doi: 10.1038/s41598-021-85081-0
Meschiari M, et al. First and second waves among hospitalised patients with COVID-19 with severe pneumonia: a comparison of 28-day mortality over the 1-year pandemic in a tertiary university hospital in Italy. BMJ Open. 2022;12: e054069.
doi: 10.1136/bmjopen-2021-054069
Greene SK, et al. Reduced COVID-19 hospitalizations among New York City residents following age-based SARS-CoV-2 vaccine eligibility: Evidence from a regression discontinuity design. Vaccine. 2022;10:100134.
Burn E, et al. Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study. Nat Commun. 2020;11:1–11.
doi: 10.1038/s41467-020-18849-z
Zayet S, et al. Clinical features of COVID-19 and influenza: a comparative study on nord franche-comte cluster. Microbes Infect. 2020;22:481–8.
doi: 10.1016/j.micinf.2020.05.016
Lambermont B, et al. Outcome improvement between the first two waves of the coronavirus disease 2019 pandemic in a single tertiary-care hospital in Belgium. Crit Care Explor. 2021;3(5):e0438.
doi: 10.1097/CCE.0000000000000438
Dai M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10:783–91.
doi: 10.1158/2159-8290.CD-20-0422
Gosain R, et al. COVID-19 and cancer: a comprehensive review. Curr Oncol Rep. 2020;22:1–15.
doi: 10.1007/s11912-020-00934-7
Mauvais-Jarvis F. Aging, male sex, obesity, and metabolic inflammation create the perfect storm for COVID-19. Diabetes. 2020;69:1857–63.
doi: 10.2337/dbi19-0023
Michalakis K, Ilias I. SARS-CoV-2 infection and obesity: Common inflammatory and metabolic aspects. Diabetes Metab Syndr. 2020;14(4):469–71.
doi: 10.1016/j.dsx.2020.04.033
Choudhary S, Sharma K, Silakari O. The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options. Microb Pathog. 2021;150: 104673.
doi: 10.1016/j.micpath.2020.104673
Liang W, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335–7.
doi: 10.1016/S1470-2045(20)30096-6
Bernard A, et al. Comparison of cancer patients to non-cancer patients among covid-19 inpatients at a national level. Cancers. 2021;13:1436.
doi: 10.3390/cancers13061436
Ángeles-Sistac D, et al. Influenza in patients with cancer after 2009 pandemic AH1N1: an 8-year follow-up study in Mexico. Influenza Other Respir Viruses. 2020;14:196–203.
doi: 10.1111/irv.12704
Kuderer NM, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. The Lancet. 2020;395:1907–18.
doi: 10.1016/S0140-6736(20)31187-9
Lee LY, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. The Lancet. 2020;395:1919–26.
doi: 10.1016/S0140-6736(20)31173-9
Bauer J, et al. Access to intensive care in 14 European countries: a spatial analysis of intensive care need and capacity in the light of COVID-19. Intensive Care Med. 2020;46(11):2026–34.
doi: 10.1007/s00134-020-06229-6
Chavez-MacGregor M, et al. Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without cancer. JAMA Oncol. 2022;8(1):69–78.
doi: 10.1001/jamaoncol.2021.5148
Sharafeldin N, et al. Outcomes of COVID-19 in patients with cancer: report from the national COVID cohort collaborative (N3C). J Clin Oncol 2021: JCO. 21.01074.
Cooksley CD, et al. Epidemiology and outcomes of serious influenza-related infections in the cancer population cancer: Interdisciplinary. Int J Am Cancer Soc. 2005;104:618–28.
Yang F, et al. Clinical characteristics and outcomes of cancer patients with COVID-19. J Med Virol. 2020;92:2067–73.
doi: 10.1002/jmv.25972
Li J, et al. Influenza in hospitalised patients with malignancy: a propensity score matching analysis. ESMO open. 2020;5:e000968.
doi: 10.1136/esmoopen-2020-000968
Diebold M, et al. Temporal trends of COVID-19 related in-hospital mortality and demographics in Switzerland—a retrospective single centre cohort study. Swiss Med Wkly 2021;151:w20572.
doi: 10.4414/smw.2021.20572
https://www.destatis.de/DE/Themen/Querschnitt/Corona/Gesellschaft/bevoelkerung-sterbefaelle.html Statistisches Bundesamt, accessed on 14 Nov 2021.
Cabezas C, et al. Associations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with covid-19 in nursing homes and healthcare workers in Catalonia: prospective cohort study. bmj 2021;374:n1868. https://doi.org/10.1136/bmj.n1868 .
doi: 10.1136/bmj.n1868
Rinott E, Youngster I, Lewis YE. Reduction in COVID-19 patients requiring mechanical ventilation following implementation of a national COVID-19 vaccination program—Israel, December 2020–February 2021. Morb Mortal Wkly Rep. 2021;70:326.
doi: 10.15585/mmwr.mm7009e3

Auteurs

Cathrin Kodde (C)

Department of Respiratory Diseases "Heckeshorn", Helios Clinic Emil-Von-Behring, Berlin, Germany. Cathrin.Kodde@helios-gesundheit.de.

Marzia Bonsignore (M)

Division of Infectious Diseases and Prevention, Helios Hospitals Duisburg, Duisburg, Germany.

Daniel Schöndube (D)

Department of Oncology and Hematology, Helios Klinikum Bad Saarow, Bad Saarow, Germany.

Torsten Bauer (T)

Department of Respiratory Diseases "Heckeshorn", Helios Clinic Emil-Von-Behring, Berlin, Germany.

Sven Hohenstein (S)

Heart Center Leipzig at University of Leipzig and Leipzig Heart Institute, Leipzig, Germany.

Andreas Bollmann (A)

Heart Center Leipzig at University of Leipzig and Leipzig Heart Institute, Leipzig, Germany.

Andreas Meier-Hellmann (A)

Helios Kliniken, Berlin, Germany.

Ralf Kuhlen (R)

Helios Health, Berlin, Germany.

Irit Nachtigall (I)

Division of Infectious Diseases and Infection Prevention, Helios Hospital Emil-Von-Behring, Berlin, Germany.
Institute of Hygiene and Environmental Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH